Randomized or quasi-experimental studies can be conducted using the TyG index as a modifiable risk marker to evaluate the reversibility of glucose-lowering/lipid-modifying strategies (e.g., employing SGLT2 inhibitors, GLP-1 receptor agonists, metformin, and statins) and their impact on AF’s occurrence and recurrence and NOAF. The gene discussed is SLC5A2; the disease is atrial fibrillation.